Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas ...

Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and ...

Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

SAN JOSE, Calif., April 1, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer ...

Anixa Biosciences (ANIX) has entered into a letter of intent with Verdi Solutions to develop personalized and off-the-shelf peptide vaccines ...

Maxim Group assumed coverage on shares of Anixa Biosciences (NASDAQ:ANIX – Free Report) in a research note released on Friday ...

Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy recommendation. Analyst Price Forecast Suggests 175.24% Upside As of March 19, ...

On Monday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a key patent application covering Anixa Biosciences, Inc.’s (NASDAQ:ANIX) ovarian cancer vaccine ...

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine. Anixa Biosciences, Inc. March 24, 2025.